Commentary: Outcome measures were flawed

BMJ. 2010 Jun 3:340:c2693. doi: 10.1136/bmj.c2693.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cost-Benefit Analysis
  • Data Collection
  • Drug Costs
  • Glatiramer Acetate
  • Health Services Accessibility / economics
  • Health Services Accessibility / organization & administration*
  • Humans
  • Interferons / economics
  • Interferons / supply & distribution
  • Magnetic Resonance Spectroscopy
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / economics
  • Outcome Assessment, Health Care*
  • Peptides / economics
  • Peptides / supply & distribution
  • Risk Sharing, Financial

Substances

  • Peptides
  • Glatiramer Acetate
  • Interferons